In the pragmatic scenario (Table 2), regardless of EF, eligible vs. noneligible patients were older, more likely female, less likely to be referred to specialty care, had more severe HF (e.g. more previous HF hospitalizations, higher NYHA class and NT‐proBNP levels) and comorbidities (e.g. more patients had eGFR < 60 vs. ≥60 mL min−1/1.73 m2, atrial fibrillation, anaemia, hypertension, diabetes, chronic obstructive pulmonary disease, history of cancer). This evidence concerns the gene NPPB and chronic obstructive pulmonary disease.